INTRODUCTION
Primary Sjögren's syndrome (PSS) is a chronic systemic autoimmune inflammatory condition characterised by lymphocytic infiltration of the exocrine glands. Other organs are variably affected in many patients and can include the kidneys, lungs, skin and the nervous system. Oral and ocular dryness are primary clinical features with a significant proportion of patients presenting with severe fatigue, musculoskeletal pain as well as organ-specific complications [1] .
Patients with PSS have a poor health-related quality of life [2] . A significant proportion of PSS patients are unable to work due to their condition [3, 4] . Aside from the direct impact of the condition on individual patients, PSS also has an indirect healthcare related cost that can be comparable with other chronic autoimmune conditions such as rheumatoid arthritis (RA). Such costs are estimated at being approximately 8 fold higher than that for healthy controls [5, 6] .
Standardized outcome tools for measuring disease-specific activity and patient reported symptoms have been recently developed by the EULAR Sjögren's syndrome study group [7] [8] [9] . The EULAR Sjögren's syndrome disease activity index (ESSDAI) is a physician-based assessment of the systemic features and severity of the condition and includes an assessment of synovitis, vasculitis, pulmonary, cutaneous, muscular, nervous, renal and biological (immunological and haematological) indices. The EULAR Sjögren's syndrome patient reported index (ESSPRI) has been developed to measure symptomatic features of Sjögren's syndrome: this includes self-assessment of dryness and levels of fatigue and pain by the patient. The EULAR sicca score is also utilised as a measure of dryness symptoms.
There are also other more generic measures of the health status of chronic conditions that are widely validated and utilised to determine Quality of Life (QoL) and the health economic impact of illness [10] . They have been used to determine the validity of specific measures of disease severity in other chronic disease states such as RA [11] . One such measure is the EuroQoL-5 dimension (EQ-5D), which is a generic health-related QoL instrument with which a Time Trade Off (TTO) value can be calculated. This value represents the amount of time an individual would be willing to sacrifice in exchange for a perfect health state in one year i.e. the number of years of perfect health that a patient believes is of equal value to 10 years in their current health state. This number can be used in turn to calculate the quality adjusted life years (QALYs). The EQ-5D also contains a patient rated visual analogue scale (VAS), the EQ5D-VAS, ranging from 0 to 100. These measures have often been used by healthcare decision makers to combine mortality and morbidity into a single interval scale.
Validation of both these relatively new and Sjögren's disease specific indices with a generic health assessment tool is important if they are to be utilised as key outcome measures of health for the clinical and economic appraisal for a chronic debilitating condition such as PSS.
This study investigates the relationship between the recently developed PSSspecific outcome measures (ESSPRI, ESSDAI and EULAR sicca score) and QoL as quantified by the TTO values and VAS scores.
PATIENTS AND METHODS

Study patient cohort
All patients with PSS in this study are participants of the UK Primary Sjögren's Syndrome Registry (UKPSSR, www.sjogrensregistry.org) [12] .The UKPSSR is an on-going cohort of patients with PSS funded by the Medical Research Council, UK, which aims to facilitate research and clinical trials. All participants fulfil the American European Consensus Group (AECG) classification criteria [13] .
Informed consent was obtained from all patients according to the principles of the Helsinki Declaration. All clinical and laboratory data were collected prospectively at the time of recruitment as previously described.
Data analysis
TTO values were derived from UK reference data [14] . The estimation of TTO values is described elsewhere along with age and gender specific values both for the UK population and for the UKPSSR cohort [2] .
We used Spearman rank correlation analysis to investigate the correlations between the TTO and EQ5D-VAS values and ESSDAI, ESSPRI and EULAR sicca score.
RESULTS
The clinical characteristics of the patient cohort are summarized in Supplementary   Table S1 . The cohort consisted of 604 women and 35 men, with an average age of 60 years (Interquartile range (IQR): 49.8-67.8 years). The median duration of symptoms was 10 years with an AECG diagnosis of 5 years. The median and IQR for the ESSDAI, ESSPRI and EULAR Sicca Scores were 3(1-7), 6(4-7) and 6(4-8) respectively. 80.4% showed evidence of systemic involvement as defined as the presence of disease activity in any of the ESSDAI domains except the glandular domain alone. When asked to rank the importance of the symptoms "Dryness", "Fatigue", "Pain" and "Mental Fatigue", 47% of the cohort ranked "Dryness" and a further 34% ranked "Fatigue" as the "Symptom most in need of improvement". The 
DISCUSSION
This study demonstrates that the recently developed and validated physician (ESSDAI), the patient (ESSPRI) reported outcome measures and the dryness score (EULAR sicca score) are significantly correlated with TTO values and VAS scores from the widely used generic health outcome measure the EQ-5D.
The ESSDAI is a clinical index designed to measure disease activity in patients with systemic complications of PSS and is modelled on physician's judgement of disease activity and was developed according to expert consensus [8] .
Articular and constitutional domains showed statistically significant correlation most reliably to both TTO and VAS scores (Supplementary Figure S3) . As may be expected the majority of domains of the ESSDAI show a negative correlation with health outcomes (i.e. higher disease activity was reflected in a poorer health outcome). Interestingly there was a positive relationship between activity in the biological domain and health status. The reasons for this relationship are not clear.
The biological domain includes measurement of serum levels of immunoglobulin and complements. One possibility is that patients with these abnormalities are more likely to present at an earlier stage in their disease course and have treatment. Not surprisingly, generic health outcome measures are unlikely to give sufficient weight to the importance of dryness symptoms (e.g. ocular and oral) when measuring quality of life. EULAR sicca score however showed a rather stronger correlation with TTO values than with VAS scores. One way to interpret this finding is that a closer relationship exists between dryness symptoms and utility values. Certainly, patients with dry eye syndrome have greater difficulty reading, carrying out professional work, and using a computer. Dryness symptoms may have an adverse impact on productivity hence it is importance to target therapies to improve this condition and thus improve overall quality of life and productivity.
A wide range of methods can be used to elicit quality-of-life weights of different health states to generate 'Quality-adjusted life years' (QALYs) with the Time trade-off method consisting of a hypothetical trade-off between living shorter and living healthier. These measures have become a powerful tool for healthcare commissioning organisations and the possibility of comparison between different types of health outcomes at a numerical level is the main advantage of using a 'common currency for health' such as the QALY. However concern has been raised about both comparing QALY outcomes related to different conditions using different assessment tools and also comparing TTO values directly [15] .
As noted above, another concern is that generic health assessment tools such as EQ-5D may potentially underestimate disease-specific measures -for example dryness. However this study has demonstrated that some of these measures correlate well, albeit imperfect, in patients with PSS.
If novel treatments are to be developed and clinically tested then scales of illness are required that are well validated, accurate and sufficiently sensitive to change. It is also of importance that they ask well-targeted questions of the condition and directly measure patient reported outcomes. It is noteworthy that here was a stronger correlation between patient reported outcome measures (ESSPRI) than there was with systemic outcome scores such as the ESSDAI.
However such scales also require validation with existing quality of life measures that can be utilised for a health economics validation, particularly since they are increasingly being used to validate the use of novel agents which are likely to incur significant treatment-related costs. Robust outcome measures are therefore a vital component to assess both clinical efficacy and where positive outcomes are found to ensure funding agreements from prescribing organisations. Our data provide further external validation of these PSS-specific indices and demonstrate that they are useful both for measuring specific disease activity and as health outcome tools for economic analysis.
Another area that would be of interest to future research is to formally evaluate the impact of early diagnosis and treatment on health outcomes, which will have particular relevance to commissioning of public funded health services.
This study has demonstrated significant correlations between these two types of measure but further analysis is required of their sensitivity to change to enable accurate measurement of health outcome states following therapeutic intervention.
Furthermore, future research to explore the potential of developing a PSS-specific QoL measure may be warranted.
CONCLUSIONS
The recently developed outcome measures from the EULAR Sjögren's syndrome study group -ESSDAI, EULAR sicca score and especially the ESSPRI -are significantly correlated with EQ-5D VAS scores and TTO values. This finding further supports the use of these instruments in intervention studies and in clinical practice. 
